You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

CLINICAL TRIALS PROFILE FOR FASLODEX


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Faslodex

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00099437 ↗ Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. Active, not recruiting AstraZeneca Phase 3 2005-02-08 The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment
New Dosage NCT01300351 ↗ Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed AstraZeneca Phase 3 2011-03-01 The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Faslodex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006903 ↗ Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Unknown status AstraZeneca Phase 2 2004-08-30 This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
NCT00006903 ↗ Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Unknown status National Cancer Institute (NCI) Phase 2 2004-08-30 This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
NCT00006903 ↗ Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Unknown status Gynecologic Oncology Group Phase 2 2004-08-30 This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Faslodex

Condition Name

Condition Name for Faslodex
Intervention Trials
Breast Cancer 58
Metastatic Breast Cancer 28
Advanced Breast Cancer 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Faslodex
Intervention Trials
Breast Neoplasms 138
Neoplasms 15
Carcinoma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Faslodex

Trials by Country

Trials by Country for Faslodex
Location Trials
United States 671
Italy 80
Spain 77
Canada 50
Japan 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Faslodex
Location Trials
California 40
Texas 36
Florida 32
New York 31
Massachusetts 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Faslodex

Clinical Trial Phase

Clinical Trial Phase for Faslodex
Clinical Trial Phase Trials
Phase 4 2
Phase 3 28
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Faslodex
Clinical Trial Phase Trials
Completed 58
Recruiting 27
Active, not recruiting 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Faslodex

Sponsor Name

Sponsor Name for Faslodex
Sponsor Trials
AstraZeneca 47
National Cancer Institute (NCI) 21
Pfizer 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Faslodex
Sponsor Trials
Other 143
Industry 136
NIH 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.